Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer

被引:15
|
作者
Rajpara, Raj S.
Schreibmann, Eduard
Fox, Tim
Stapleford, Liza J.
Beitler, Jonathan J.
Curran, Walter J.
Higgins, Kristin A. [1 ]
机构
[1] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA
来源
RADIATION ONCOLOGY | 2014年 / 9卷
关键词
Lung cancer; Locally advanced; Locoregional failure; PET/CT; Radiation; Chemotherapy; STANDARDIZED UPTAKE VALUE; PHASE-III; CONCURRENT CHEMOTHERAPY; FDG-PET; TRIAL; RADIOTHERAPY; INDUCTION; SURVIVAL; THERAPY; DISEASE;
D O I
10.1186/1748-717X-9-187
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Locoregional tumor failure (LRF) after definitive chemoradiation for patients with stage III NSCLC remains unacceptably high. This analysis sought to further define where LRF occurs relative to radiation dose received and pre-treatment PET scan-defined maximum standard uptake value (SUVmax). Methods: This was a retrospective study analyzing patients with stage III NSCLC treated with definitive radiation between 2006 and 2011. LRF was defined as failure within the ipsilateral lung, hilum or mediastinum. The CT simulation scan with the radiation dose distribution was registered to the CT or PET/CT documenting LRF. The region of LRF was contoured, and the dose to 95% of the volume (D95) of LRF was extracted. The pre-treatment SUVmax was also extracted for the anatomic region of LRF. Results: Sixty-one patients were identified. Median follow-up time was 19.1 months (range 2.37-76.33). Seventy four percent of patients were treated with 3-D conformal technique (3DCRT), 15% were treated with Intensity Modulated Radiotherapy (IMRT), and 11% were treated with a combination of 3DCRT and IMRT. Median prescribed radiation dose for all patients was 66 Gy (39.6-74). Concurrent chemotherapy was delivered in 90% of patients. Twenty-two patients (36%) developed a LRF, with a total of 39 anatomic regions of LRF identified. Median time to LRF was 11.4 months (3.5-44.6). Failures were distributed as follows: 36% were in-field failures, 27% were out-of-field failures, 18% were in-field and out-of-field failures, and 18% were in-field and marginal (recurrences within the field edge) failures. There were no isolated marginal failures. Of the patients that developed a LRF, 73% developed a LRF with an in-field component. Sixty-two percent of LRFs were nodal. The median pre-treatment SUVmax for the anatomic region of LRF for patients with an in-field failure was 13. The median D95 of in-field LRF was 63 Gy. Conclusions: LRF after definitive chemoradiation are comprised primarily of in-field failures, though out-of field failures are not insignificant. Marginal failures are rare, indicating field margins are appropriate. Although radiation dose escalation to standard radiation fields has not yielded success, using PET parameters to define high-risk regions remains worthy of further investigation.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer
    Raj S Rajpara
    Eduard Schreibmann
    Tim Fox
    Liza J Stapleford
    Jonathan J Beitler
    Walter J Curran
    Kristin A Higgins
    Radiation Oncology, 9
  • [2] Pulmonary Resection for a Residual Tumor after Definitive Radiation in Locally Advanced Non-Small Cell Lung Cancer
    Tagawa, Tetsuzo
    Ito, Kensaku
    Fukuzawa, Kengo
    Motohiro, Akira
    THORACIC AND CARDIOVASCULAR SURGEON, 2018, 66 (02): : 170 - 173
  • [3] Effectiveness of radiation therapy alone for elderly patients with unresected stage III non-small cell lung cancer
    Sigel, Keith
    Lurslurchachai, Linda
    Bonomi, Marcelo
    Mhango, Grace
    Bergamo, Cara
    Kale, Minal
    Halm, Ethan
    Wisnivesky, Juan
    LUNG CANCER, 2013, 82 (02) : 266 - 270
  • [4] A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer
    Peng, Jonathan
    Pond, Greg
    Donovan, Elysia
    Ellis, Peter M.
    Swaminath, Anand
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 985 - 992
  • [5] Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Mooradian, Meghan J.
    Cai, Ling
    Wang, Alice
    Qiao, Yao
    Chander, Pratibha
    Whitaker, Ryan M.
    JAMA NETWORK OPEN, 2024, 7 (04) : e247542
  • [6] Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy
    Nakamura, Tatsuya
    Fuwa, Nobukazu
    Kodaira, Takeshi
    Tachibana, Hiroyuki
    Tomoda, Takuya
    Nakahara, Rie
    Inokuchi, Haruo
    LUNG, 2008, 186 (02) : 91 - 96
  • [7] Clinical Outcome of Stage III Non-small-cell Lung Cancer Patients After Definitive Radiotherapy
    Tatsuya Nakamura
    Nobukazu Fuwa
    Takeshi Kodaira
    Hiroyuki Tachibana
    Takuya Tomoda
    Rie Nakahara
    Haruo Inokuchi
    Lung, 2008, 186 : 91 - 96
  • [8] Heart substructural dosimetric parameters and risk of cardiac events after definitive chemoradiotherapy for stage III non-small cell lung cancer
    Jang, Bum-Sup
    Cha, Myung-Jin
    Kim, Hak Jae
    Oh, Seil
    Wu, Hong-Gyun
    Kim, Eunji
    Kim, Byoung Hyuck
    Kim, Jae Sik
    Chang, Ji Hyun
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : 126 - 132
  • [9] Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy
    Dang, Jun
    Li, Guang
    Zang, Shuang
    Zhang, Shuo
    Yao, Lei
    RADIATION ONCOLOGY, 2014, 9
  • [10] Definitive treatment patterns and survival in stage II non-small cell lung cancer
    Yan, Sherry X.
    Qureshi, Muhammad M.
    Suzuki, Kei
    Dyer, Michael
    Truong, Minh Tam
    Litle, Virginia
    Mak, Kimberley S.
    LUNG CANCER, 2018, 124 : 135 - 142